117 related articles for article (PubMed ID: 9309118)
1. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients.
Patiño-García A; Sierrasesúmaga L
Cancer Genet Cytogenet; 1997 Oct; 98(1):50-5. PubMed ID: 9309118
[TBL] [Abstract][Full Text] [Related]
2. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the p15, p16,and p18 genes in osteosarcoma.
Miller CW; Aslo A; Campbell MJ; Kawamata N; Lampkin BC; Koeffler HP
Cancer Genet Cytogenet; 1996 Feb; 86(2):136-42. PubMed ID: 8603340
[TBL] [Abstract][Full Text] [Related]
5. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
6. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
7. p16 mutations/deletions are not frequent events in prostate cancer.
Tamimi Y; Bringuier PP; Smit F; van Bokhoven A; Debruyne FM; Schalken JA
Br J Cancer; 1996 Jul; 74(1):120-2. PubMed ID: 8679444
[TBL] [Abstract][Full Text] [Related]
8. Detection of TP53 gene mutations in human sarcomas.
Castresana JS; Rubio MP; Gómez L; Kreicbergs A; Zetterberg A; Barrios C
Eur J Cancer; 1995; 31A(5):735-8. PubMed ID: 7640047
[TBL] [Abstract][Full Text] [Related]
9. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
10. p16INK4 and p15INK4B alterations in primary gynecologic malignancy.
Wong YF; Chung TK; Cheung TH; Nobori T; Yim SF; Lai KW; Phil M; Yu AL; Diccianni MB; Li TZ; Chang AM
Gynecol Oncol; 1997 May; 65(2):319-24. PubMed ID: 9159345
[TBL] [Abstract][Full Text] [Related]
11. p21WAF1 mutation is not a predominant alteration in pediatric bone tumors.
Patiño-García A; Sotillo-Piñeiro E; Sierrasesúmaga-Ariznabarreta L
Pediatr Res; 1998 Mar; 43(3):393-5. PubMed ID: 9580228
[TBL] [Abstract][Full Text] [Related]
12. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
15. Mutations and altered expression of p16INK4 in human cancer.
Okamoto A; Demetrick DJ; Spillare EA; Hagiwara K; Hussain SP; Bennett WP; Forrester K; Gerwin B; Serrano M; Beach DH
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11045-9. PubMed ID: 7972006
[TBL] [Abstract][Full Text] [Related]
16. Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors.
Chaubert P; Guillou L; Kurt AM; Bertholet MM; Metthez G; Leisinger HJ; Bosman F; Shaw P
Am J Pathol; 1997 Sep; 151(3):859-65. PubMed ID: 9284835
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
18. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of p16INK4 in hepatocellular carcinoma.
Hui AM; Sakamoto M; Kanai Y; Ino Y; Gotoh M; Yokota J; Hirohashi S
Hepatology; 1996 Sep; 24(3):575-9. PubMed ID: 8781327
[TBL] [Abstract][Full Text] [Related]
20. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
